Imarsa

Fulvestrant, the active ingredient in Imarsa, is a selective estrogen receptor degrader (SERD) presented as an intramuscular injection for intramuscular use. Approved in the European Union, it binds to estrogen receptors and promotes their degradation, thereby blocking estrogen‑mediated signaling. It is indicated for the treatment of estrogen receptor‑positive metastatic breast cancer in adult patients.

GNH USA supplies Imarsa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and procurement teams worldwide. The company adheres to EU quality standards and provides regulatory documentation, cold‑chain logistics and post‑market support for its injectable oncology products.

Imarsa (fulvestrant) is used in hormonal therapy targeting estrogen receptor pathways in breast cancer.

Estrogen receptor‑positive metastatic breast cancer: improves disease control and delays progression in adult patients. Postmenopausal women with advanced ER+ breast cancer: provides an alternative to aromatase inhibitors when resistance develops. Hormone‑responsive advanced breast cancer: reduces tumor growth by degrading estrogen receptors. Advanced estrogen receptor‑positive breast cancer after prior endocrine therapy: offers continued hormonal control. Patients with disease progression on tamoxifen: provides a different mechanism of action to overcome resistance.

The safety profile of Imarsa (fulvestrant) includes both frequent and less common adverse reactions observed in clinical use.

Common Side Effects: - Injection site pain - Hot flashes - Nausea - Fatigue - Musculoskeletal pain - Headache

Serious or Rare Side Effects: - Hepatotoxicity - Thromboembolic events - Interstitial lung disease - Severe allergic reactions (anaphylaxis) - QT interval prolongation

When prescribing Imarsa, clinicians should observe several precautionary measures to minimise risk and ensure appropriate use. - Liver function monitoring: assess baseline enzymes and repeat periodically during therapy. - Thromboembolic risk assessment: evaluate history of clotting disorders before initiation. - Cardiac evaluation: monitor for QT prolongation in patients with cardiac disease. - Hypersensitivity: discontinue if severe allergic reaction occurs. - Pregnancy and lactation: avoid use due to unknown safety; consider effective contraception. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Fulvestrant may interact with other medicines that affect its metabolism or pharmacodynamic pathways.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce fulvestrant exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase exposure and risk of toxicity. - Concurrent estrogen therapy: may antagonize fulvestrant’s anti‑estrogenic effect.

Moderate Interactions (Monitor Closely): - Warfarin: monitor INR as fulvestrant may alter anticoagulant effect. - QT‑prolonging agents (e.g., macrolides, fluoroquinolones): observe cardiac rhythm. - CYP2D6 inhibitors: may modestly affect metabolism; watch for side effects.